CLINICAL_TRIALS
trial_result
· 2019-03-21
Clinical Trial Update: A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma [Phase 3]
Summary
Phase 3 trial update for reslizumab in severe eosinophilic asthma in patients aged 12 and older; study terminated with results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Eosinophils, Asthma | Phase 3 | Status: TERMINATED | Results posted: 2019-03-21